Document:

Agreement for Termination of Lease - BMR-Bridgeview Technology Park, LLC

 Exhibit 10.30 
 AGREEMENT FOR TERMINATION OF LEASE AND 
 VOLUNTARY SURRENDER OF PREMISES 
 This Agreement for Termination of Lease and Voluntary Surrender of Premises (this
“Agreement”) is made as of the 6th day of March, 2009 (the “Execution Date”), by and between
BMR-Bridgeview Technology Park LLC, a Delaware limited liability company (“BMR”), and Cell Genesys, Inc., a Delaware corporation (“Cell Genesys”), with reference to the following: 
 RECITALS 
 A. BMR (as
successor-in-interest to F&S Hayward, LLC, a California limited liability company) and Cell Genesys are parties to that certain Lease Agreement dated as of June 29, 2000, as amended by that certain First Amendment to Lease dated as of
January 2, 2001 (as amended, and as the same may have been further amended, supplemented or otherwise modified from time to time, the “Lease”) for premises (the “Premises”) located at that certain
real property commonly known as 24570 Clawiter Road, Hayward, California, being more particularly described in the Lease. 
 B. Cell Genesys
desires to terminate the Lease earlier than the expiration date set forth in the Lease, and BMR is willing to agree to the early termination of the Lease as set forth in this Agreement. 
 AGREEMENT 
 NOW, THEREFORE, in consideration of the foregoing, in further
consideration of the mutual promises made herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, BMR and Cell Genesys agree as follows: 
 1. Termination Date. BMR and Cell Genesys hereby agree that, subject only to fulfillment or waiver of the Termination Conditions (as hereinafter
defined), the Lease shall terminate automatically (except for the Surviving Obligations, as hereinafter defined) without further action of BMR or Cell Genesys at 11:59 p.m. PST on March 6, 2009 (the “Termination Date”);
provided, however, BMR shall look solely to the Termination Fee for any amounts of Rent coming due in March 2009. If the Termination Conditions have not been fulfilled or waived by March 31, 2009, then, upon written notice by BMR or Cell
Genesys to the other party, this Agreement shall be null and void and of no further force or effect. If neither party elects to void this Agreement pursuant to the preceding sentence by 11:59 p.m. PST on April 7, 2009, such right to void this
Agreement shall be waived and this Agreement shall remain in full force and effect. 
 2. Termination. On the Termination Date, the
Lease shall terminate, except for the Surviving Obligations. From and after the Termination Date, Cell Genesys will cease occupying the Premises pursuant to the Lease. 

 3. Surrender; FF&E. Notwithstanding anything in the Surrender Obligations (as hereinafter
defined) to the contrary, (a) Cell Genesys shall surrender the Premises and all alterations and improvements therein to BMR on the Termination Date in their current “as is” condition with all Premises systems and equipment therein in
good working order (to the extent the responsibility of Cell Genesys under the Lease) and BMR shall accept the Premises and such alterations and improvements in such condition, (b) Cell Genesys shall not remove any Tenant improvements or
alterations from the Premises, (c) Cell Genesys shall not remove any fixed asset listed on Exhibit A hereto (the “Fixed Asset List”) nor remove any other similar additions and improvements built in and existing in
the Premises as of the Execution Date, as such fixed assets have become an integral part of the real property referred to as the “Premises”, (d) Cell Genesys shall deliver to BMR those items set forth on the Building Turnover List
attached as Exhibit B hereto (“Building Turnover List”), and BMR shall be entitled to use and disclose to third parties any marketing materials prepared by, or on behalf of Cell Genesys in connection with the Premises,
but without any warranty or representation by Cell Genesys (the items listed on the Fixed Asset List and Building Turnover List being referred to herein collectively as the “FF&E”), and (e) Cell Genesys shall not be
required to perform any restoration or any alterations or installations to the Premises or pay any removal costs thereof. The obligations of Cell Genesys under Section 27 of the Lease (as modified by Section 26 of the First Amendment
thereto) and Section 10.2 of the Lease (as modified by Section 16 of the First Amendment), as further modified by the preceding sentence, are hereinafter sometimes referred to as the “Surrender Obligations”. The
parties acknowledge that the FF&E shall become the property of BMR effective upon the Termination Date, subject only to fulfillment or waiver of the Termination Conditions, and that Cell Genesis shall keep in effect any insurance required by the
Lease until the fulfillment or waiver of the Termination Conditions. Cell Genesys does hereby grant, bargain, sell, transfer, assign, convey, set over and deliver unto BMR as of the Termination Date all of Cell Genesys’ right, title and
interest in and to the FF&E subject only to fulfillment or waiver of the Termination Conditions. 
 4. No Further Obligations. BMR
and Cell Genesys agree that BMR and Cell Genesys are excused as of the Termination Date from any further obligations with respect to the Lease, excepting only the obligations herein, the Surrender Obligations and the indemnity obligations of Cell
Genesys under Sections 13 and 27.5 of the Lease, as modified by Section 26 of the First Amendment (collectively with the Surrender Obligations, the “Surviving Obligations”). In addition, nothing herein shall be deemed to
limit or terminate any common law or statutory rights BMR may have with respect to Cell Genesys in connection with the Surviving Obligations. 
 5. Removal of Movable Personal Property. Cell Genesys agrees that the Premises shall be surrendered free of the movable personal property of Cell Genesys other than the FF&E, which movable personal property Cell Genesys shall
remove from the Premises on or before the Termination Date. Any movable personal property of Cell Genesys other than the FF&E remaining in the Premises as of the Termination Date shall be deemed to be abandoned by Cell Genesys and may be
disposed of by BMR, in BMR’s sole discretion, without obligation or liability to Cell Genesys. 
  

 2 

 6. Release of Liability. As of the Termination Date, except as set forth herein and except for the
Surviving Obligations, each of BMR and Cell Genesys releases and exculpates the other from any claim, action, cause of action, obligation, cost, demand and liability of every type and nature, known and unknown, arising from or connected with the
Lease or from the termination of the Lease. The foregoing releases extend to all rights of BMR and Cell Genesys under Section 1542 of the California Civil Code and any similar law of any state or territory of the United States, which are hereby
expressly waived and relinquished by BMR and Cell Genesys. Section 1542 reads: 
 A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE
CREDITOR DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE, WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR. 
  

					
			
	 	 		 	 
	Cell Genesys’ Initials	 		 	BMR’s Initials

 7. Termination Conditions. The termination of the Lease shall be subject to the fulfillment
or waiver of the following conditions for the benefit of BMR (collectively, the “Termination Conditions”): (a) BMR shall have obtained consent from BMR’s lender to enter into this Agreement, (b) Cell Genesys
shall have paid the Termination Fee (as defined below) to BMR within 2 business days after written notification from BMR that BMR has obtained consent from BMR’s lender to enter into this Agreement, and (c) Cell Genesys shall have
delivered to BMR the FF&E. 
 8. Termination Fee. Cell Genesys shall pay to BMR in immediately available funds, in consideration
of BMR’s agreement to terminate the Lease, a payment in the amount of Two Hundred Eighty-Nine Thousand Four Hundred Sixty-Four Dollars ($289,464) (the “Termination Fee”). BMR acknowledges that all Base Rent and
Additional Rent payable by Cell Genesys under the Lease up to and including February 28, 2009, have been paid. 
 9. Return of Cash
Deposit. BMR and Cell Genesys acknowledge and agree that BMR is holding a security deposit in the form of cash in the amount of $50,174 (the “Cash Deposit”). Notwithstanding anything in the Lease to the contrary, provided
that the Lease is terminated in accordance with this Agreement, BMR shall retain the Cash Deposit as part of the Termination Fee. 
 10.
No Assignment, Subletting or Encumbrances. Cell Genesys represents and warrants that it has not assigned, subleased, mortgaged, pledged, encumbered or otherwise transferred any interest in the Lease or the FF&E and that Cell Genesys holds
the entire lessees’ interests in the Premises conveyed by the Lease as of the Execution Date. Notwithstanding anything to the contrary set forth in the Lease, Cell Genesys shall not assign, sublease, mortgage, pledge, encumber or otherwise
transfer any interest in the Lease or the FF&E prior to the Termination Date. Cell Genesys further represents and warrants that its title to the FF&E is free and clear of all liens, mortgages, pledges, security interests, prior assignments
(other than those that have been disclosed to BMR in writing), encumbrances and claims of any nature, and agrees to indemnify BMR for all losses, costs and expenses (including reasonable attorneys’ fees) 

  

 3 

 
incurred by BMR as a result of a breach of such representation and warranty. Cell Genesys hereby assigns and transfers to BMR any third-party warranty to or
guaranty of the FF&E to the extent transferrable and hereby expressly disclaims any other warranty, express or implied, whatsoever with respect to the FF&E. 
 11. No Further Modification/Counterparts/Authorization/Waiver. This Agreement may not be modified or terminated except in writing signed by all parties. This Agreement may be executed in counterparts which,
taken together, will constitute one agreement binding on the parties. The persons signing below represent and warrant that they are duly authorized to execute this Agreement. No covenant or condition of this Agreement in favor of any party shall be
deemed waived unless expressly waived in writing by an officer of such party. 
 12. Successors and Assigns. The covenants and
agreements herein contained shall inure to the benefit and be binding upon the parties and their respective successors and assigns, whether by merger, sale, consolidation or otherwise. 
 13. Attorneys’ Fees. In the event of a dispute between the parties, the prevailing party shall be entitled to have its reasonable
attorneys’ fees and costs paid by the other party. 
 14. Conflict of Laws. This Agreement shall be governed by the laws of the
state in which the Premises are located. 
 15. Headings. Section headings in this Agreement are for convenience of reference only,
and shall not be construed to affect or modify the substantive meaning of any Section hereof. 
 16. Severability. If any clause or
provision of this Agreement is illegal, invalid or unenforceable under present or future laws, then and in that event, it is the intent of the parties hereto that the remainder of this Agreement, and the validity, enforceability and legality
thereof, shall not be affected or impaired thereby in any way. 
 17. Incorporation by Reference. All exhibits and addenda attached
hereto are hereby incorporated into this Agreement and made a part hereof. 
 18. Brokers. Cell Genesys and BMR each represents and
warrants that no broker, agent or other person (collectively, “Broker”) is owed any commission or other form of compensation in connection with the execution and delivery of this Agreement. Cell Genesys and BMR each hereby
agree to indemnify and hold the other harmless from and against any claims by any Broker claiming a commission or other form of compensation by virtue of having dealt with Cell Genesys or BMR, as applicable, with regard to this Agreement.

  

 4 

 19. Notices. All notices or other communications between the parties shall be in writing and shall
be deemed duly given upon delivery or refusal to accept delivery by the addressee thereof if delivered in person, or upon actual receipt if delivered by reputable overnight guaranty courier, addressed and sent to the parties at the following
addresses: 
 If to BMR: 
 BMR-Bridgeview Technology Park LLC 
 17190 Bernardo Center Drive 
 San Diego, CA 92128 
 Attn: Vice President,
Development 
 with a copy to: 
 BMR-Bridgeview Technology Park LLC 
 17190 Bernardo Center Drive 
 San Diego, CA 92128 
 Attn: Vice President,
Real Estate Counsel 
 If to Cell Genesys: 
 400 Oyster Point Boulevard, Suite 525 
 South San Francisco, CA 94080 
 Attn: Sharon Tetlow 
 with a copy to:

 Holme Roberts & Owen LLP 
 560 Mission Street 25th Floor 
 San Francisco, CA 94105 
 Attn: Kenneth R. Whiting. Esq. 
 BMR and Cell Genesys may
from time to time by written notice to the other designate another address for receipt of future notices. 
 20. Lender Third Party
Beneficiary. By execution of this Agreement, Cell Genesys acknowledges and confirms that (a) the consent of BMR’s lender is a Termination Condition, (b) the Surviving Obligations expressly benefiting the Indemnitees (as defined in
the Lease) in the Lease, shall inure to the benefit of BMR’s lender and (c) BMR’s lender is an intended third party beneficiary of such provisions and may enforce such provisions directly against Cell Genesys. 
 21. Consultant Consent. BMR, or an affiliate of BMR, may engage as consultants certain employees or former employees designated by Cell Genesys
(the “Designated Personnel”) to assist in the assessment of the suitability of the Premises for various future uses and tenants (the “Suitability Assessment”). Cell Genesys hereby (a) consents to the
participation of such Designated Personnel in the Suitability Assessment to the extent that such participation is limited to providing Suitability Information (as defined below) and (b) waives any duty of confidentiality of the Designated
Personnel to Cell Genesys with regard to Suitability Information that may be provided by the Designated Personnel in connection with the Suitability Assessment. For the purposes of this Section 21, “Suitability Information” shall mean
information related to the physical characteristics of the manufacturing plant and equipment, the general operational aspects of the manufacturing plant and equipment, and the general capacity and utility flows associated with the manufacturing
plant and equipment, but expressly excluding 

  

 5 

 
any information related to Cell Genesys personnel matters, financial matters (except financial matters relating to the lease or purchase of the FF&E),
clinical data, proprietary processes, intellectual property (including, without limitation, trade secrets) and any other information not reasonably related to the physical characteristics of the manufacturing plant and equipment and general
operational aspects of the activities previously employed at the Premises by Cell Genesys. 
 [Remainder of page intentionally left
blank.] 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

  

			
	BMR:
	
	 BMR-BRIDGEVIEW TECHNOLOGY PARK LLC,
 a
Delaware limited liability company

		
	By:	 	/S/ KENT GRIFFIN
	Name:	 	Kent Griffin
	Its:	 	President

  

			
	CELL GENESYS:
	
	 CELL GENESYS, INC.,
 a Delaware
corporation

		
	By:	 	/S/ SHARON TETLOW
	Name:	 	Sharon Tetlow
	Its:	 	CFO

  

 7Separation Agreement

 Exhibit 10.1 
 SEPARATION AGREEMENT 
 THIS SEPARATION AGREEMENT (this “Agreement”) is
entered into on March 3, 2009, by and between Assurant, Inc. (the “Company”) and Philip Bruce Camacho (the “Employee”). 
 WHEREAS, the Employee served as an officer and employee of the Company and its subsidiaries and predecessors for 18 years, and currently holds the position of Executive Vice President and Chief Financial Officer of
the Company; 
 WHEREAS, in July 2007, the Employee was placed on administrative leave by the Company after receiving a Wells Notice
resulting from an investigation by the United States Securities and Exchange Commission (the “SEC”) concerning the Company’s accounting for cash flows under a finite reinsurance treaty that expired at the end of 2004 (the
“SEC Investigation”); 
 WHEREAS, the Employee is cooperating with the Company and the SEC in connection with the SEC
Investigation; 
 WHEREAS, the Employee wishes to resign his employment with the Company, and the parties hereto wish to conclude the
Employee’s employment on the terms set forth in this Agreement and to provide for certain post-employment covenants; and 
 WHEREAS,
simultaneously with this Agreement, the Employee has entered into a consulting agreement with the Company, dated as of the date hereof (the “Consulting Agreement”). 
 NOW, THEREFORE, in consideration of the mutual covenants and representations contained in this Agreement and the Consulting Agreement, the parties hereto
agree as follows: 
 1.    Termination of Employment 
 The Employee’s employment with the Company shall cease effective on March 15, 2009 (the “Termination Date”). Effective as of the Termination Date, the Employee hereby resigns his position as
Executive Vice President and Chief Financial Officer of the Company, as well as from any and all positions held by the Employee as an officer or director of any subsidiary of the Company. From and after the Termination Date, the Employee shall not
hold any office or position with, nor maintain any other status as an employee or agent of, the Company or any subsidiary or affiliate of the Company. Effective on the date hereof, the letter agreement by and between the Employee and American
Bankers Insurance Group, Inc., (a subsidiary of the Company), dated October 17, 1997 (the “Employment Agreement”), is hereby terminated and shall be of no further force or effect. 

 2.    Severance Payment 
 Subject to the payment restrictions set forth in Section 5 hereof, the Company shall pay to the Employee, as severance pay in connection with
termination of employment, an aggregate amount of $5,000,000 (the “Severance Payment”). The Severance Payment shall be payable in six (6) consecutive monthly installments of $833,333.33 each, beginning on July 2, 2009, and
shall be subject to applicable tax withholding requirements. The Severance Payment shall be in lieu of any other severance payments to which the Employee may be entitled under the Employment Agreement or under any severance plan, program or
agreement of the Company or any subsidiary. 
 3.    Employee Benefits 
 A.    Nonqualified Plans. The Employee shall be entitled to payment of his accrued benefits pursuant to the terms of the
Assurant Executive 401(k) Plan, the Assurant Executive Pension Plan and the Assurant Supplemental Executive Retirement Plan (the “Plans”). All payments under the Plans shall be made as soon as practicable following the Termination
Date, provided that the commencement of any such payment that is subject to the requirements of Section 409A of the Internal Revenue Code and the regulations promulgated thereunder (Section 409A”) shall be delayed until the
date that is date that is six (6) months and one day following the Employee’s “separation from service” within the meaning of Section 409A (which the parties agree occurred on January 1, 2009). 
 B.    COBRA Continuation. The Company shall reimburse the Employee for COBRA healthcare continuation premiums at the
then-applicable rates based on the Employee’s coverage election for a period of eighteen (18) months following the Termination Date, provided, that the Employee makes a valid COBRA election, which has been provided to the Employee.

 C.    Other Benefits. Except as specifically provided herein, this Agreement shall have no effect on the rights
of the Employee to payments or other benefits due to the Employee pursuant to the terms of any employee benefit plans of the Company, including, without limitation the tax-qualified pension plans in which the Employee participates. The Employee
shall be entitled to receive such benefits and payments as the Employee is entitled pursuant to the terms of such employee benefit plans. No portion of the Severance Payment shall be taken into account in determining the amount of any employee
benefit. The Employee shall receive a check within fifteen (15) days after the Termination Date for the amount of his unused vacation and paid time off. 
 4.    Equity Rights 
 A.    Exercise of SARs. All outstanding, vested stock
appreciation rights (“SARs”) shall remain exercisable for ninety (90) days following the Termination Date, pursuant to the terms of the applicable SAR agreements; provided, that, at the Employee’s option, the
SARs may be settled in cash (less applicable withholding taxes) upon exercise, in an amount equal to the excess of the Fair Market Value over the exercise price for each SAR so exercised, multiplied by the number of shares thereof. For purposes
hereof, the “Fair Market Value” shall 

  

 2 

 
equal the closing trading price of the Company’s common stock on the New York Stock Exchange on the date of exercise. All payments under this
Section 4.A. shall be made within fifteen (15) days following the date of exercise by wire transfer in accordance with wire transfer instructions furnished to the Company on or prior to the date of exercise. All other stock
appreciation rights and other equity grants held by the Employee that are not yet vested as of the Termination Date shall be cancelled and shall be of no further force or effect. 
 B.    Trading Restrictions. Effective immediately following the Termination Date, the Employee shall no longer be subject to
the Company’s securities trading policies, except with respect to any restrictions that apply to material non-public information that the Employee may possess. 
 5.    Payment Restrictions 
 A.    Potential Escrow of
Severance Payment. In the event that the SEC files a civil complaint alleging that the Employee has engaged in securities fraud under Section 17(a)(1) of the Securities Act of 1933 and/or Section 10(b) of the Securities Exchange Act of
1934 and Rule 10b-5 thereunder involving the Company (an “SEC Action”), any installments of the Severance Payment that are unpaid as of the date of the filing of the SEC Action shall not be paid directly to the Employee and shall
instead be deposited into a third party (approved by the Employee) escrow account pending resolution of the SEC Action. The terms of any such escrow arrangement shall be determined by the Company in good faith and shall provide for the payment of a
reasonable rate of interest on the escrowed amounts, and the amounts to be deposited into the escrow account shall be subject to withholding tax, if any, as determined by the Company in good faith to be required under applicable tax laws. The escrow
agreement shall provide that the amount of the Severance Payment held in the escrow account, plus accrued interest, shall be released from escrow and paid to the Employee in the event of, and on a date that is no later than fifteen (15) days
following the entry of a non-appealable, final resolution of the SEC Action with respect to the Employee in which there is neither a final, non-appealable judicial finding nor a final, non-appealable jury verdict that Employee has violated or is
liable under Section 17(a)(1) of the Securities Act of 1933 or Section 10(b) of the Securities Exchange Act or 1934. 
 B.    Forfeiture and Reimbursement of Severance Payment and Benefits. In the event of a non-appealable, final judicial finding that the Employee has engaged in fraud under Section 17(a)(1) of the Securities
Act of 1933 and/or Section 10(b) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder (a “Forfeiture Event”), the Company may, in its discretion, cause the Employee to irrevocably forfeit his entitlement to any
unpaid Severance Payment under Section 2 hereof, and within fifteen (15) days of the Forfeiture Event, reimburse the Company in immediately available funds for all Severance Payments previously made to the Employee. 
 C.    Sarbanes-Oxley. This Agreement is not intended to, and does not, alter or modify either party’s rights or
liabilities, if any, under section 304 of the Sarbanes-Oxley Act of 2002. 
  

 3 

 6.    Employee Representations 
 The Employee represents and warrants that he has not knowingly violated or caused the Company to violate any federal or state securities law. 

7.    Employee Covenants 
 A.    Confidential Information. At any time prior to or after the Termination Date, the Employee shall not, (a) except as required by law or by order of a government agency or court of competent jurisdiction,
disclose to any person, firm, corporation or other business entity any Confidential Information proprietary to the Company concerning the business, finances, products, services, operations, clients, employees, or affairs of the Company or any
subsidiary or affiliate thereof, for any reason or purpose whatsoever, or (b) make use of any such non-public information for personal purposes or for the benefit of any person, firm, corporation or other business entity, except the Company or
any subsidiary or affiliate thereof. “Confidential Information” means information not generally known or available outside the Company and information entrusted to the Company in confidence by third parties. Confidential Information
includes, without limitation: Company inventions, technical data, trade secrets, know-how, research, product or service ideas or plans, software codes and designs, developments, processes, formulas, techniques, lists of, or information relating to,
suppliers and customers, price lists, pricing methodologies, cost data, market share data, marketing plans, licenses, contract information, business plans, financial forecasts, historical financial data, budgets or other business information
disclosed to the Employee by the Company. 
 Further, except as is necessary to obtain new employment or as required by law or by order of a
government agency or court of competent jurisdiction, the Employee shall not disclose the reasons for or terms of his departure from the Company without the written consent of the Company, and will not disclose the contents or substance of this
Agreement or the Release (as defined in Section 11 hereof) to anyone except his immediate family or any tax, legal or other counsel he has consulted regarding the meaning or effect hereof, and he will instruct each of the foregoing not
to disclose the same. The Employee shall, within ten (10) days following to the Termination Date, return to the Company any documents, records, files and other information (whether recorded or stored in paper or electronic form) and any
property belonging or relating to the Company, its affiliates, customers, clients or employees, except as requested in the performance of the Employee’s obligations under the Consulting Agreement. The Employee acknowledges that all such
materials are, and will remain, the exclusive property of the Company, and the Employee may not retain originals or copies of such materials. 
 B.    Nonsolicitation and Non-Hire Restriction. For a period of two (2) years following the Termination Date (the “Restricted Period”), the Employee shall not, whether on his own behalf or on
behalf of or in conjunction with any other person or entity, directly or indirectly, 
 (i)    cause any customer,
policyholder, client, or agent doing business or having business relationship with the Company or any of its subsidiaries or affiliates to alter or terminate such person’s relationship with the Company or its subsidiaries or affiliates in any
way, or 
  

 4 

 (ii)    solicit or hire any employee who (a) was employed by the Company or any
subsidiary or affiliate thereof as of the Termination Date or (b) left the employment of the Company or any subsidiary or affiliate thereof on or within two months prior to the Termination Date. 
 C.    Nondisparagement. The Employee shall not publicly or privately disparage or denigrate the Company or its officers or
directors in respect of their integrity or business practices, performance, skills, acumen, experience or success, or concerning any officers or directors personally. The Company shall not and shall direct its officers and directors not to, publicly
disparage or denigrate the Employee in respect of the Employee’s integrity or business practices, performance, skills, acumen, experience or success, or concerning the Employee personally. The respective parties shall only be responsible for,
and bear any and all liability, for, any breach of this Section 7.C if such breach is knowingly and willfully committed and involves a material public disparagement of the other party. Notwithstanding the foregoing, neither the Company
nor the Employee shall be entitled to terminate, rescind, repudiate or seek judicial invalidation of this Agreement or any of its provisions as a remedy for any breach or alleged breach of this Section 7.C. Notwithstanding the foregoing,
nothing in this Section 7.C. is intended to prohibit, limit or prevent either party from providing truthful testimony in a court of law, truthful statements to a government official, regulatory or law enforcement agency or pursuant to voluntary
requests by SEC staff or a properly issued subpoena, including, without limitation, in connection with the SEC Investigation, and such testimony or statements shall not be deemed to be a violation of this Section 7.C. 
 D.    Consulting and Cooperation. The Employee agrees to enter into and perform his obligations under the Consulting
Agreement. The Employee agrees that he shall not act as an expert witness, consultant or otherwise in any litigation against the Company. 
 8.    Enforcement of Restrictions 
 A.    Reasonableness. The Employee hereby
acknowledges and agrees that: (i) the restrictions provided in this Agreement are reasonable in time and scope in light of the necessity of the protection of the business of the Company; (ii) his ability to work and earn a living will not
be unreasonably restrained by the application of these restrictions; and (iii) if a court concludes that any of the restrictions in this Agreement are overbroad or unenforceable for any reason, the court shall modify the relevant provision to
the least extent necessary and then enforce it as modified. 
 B.    Injunctive and Other Relief. The Employee
recognizes and agrees that should he fail to comply with the restrictions set forth herein, which restrictions are vital to the protection of the Company’s business, the Company will suffer irreparable injury and harm for which there is no
adequate remedy at law. Therefore, the Employee agrees that in the event of the breach or threatened breach by him of any of the terms and conditions of Sections 7.A or 7.B hereof, the Company shall be entitled to preliminary and
permanent injunctive relief against him and any other relief as may be awarded by a court having jurisdiction over the dispute. In the event of a judicial finding of a material breach by the Employee of the provisions of Sections 7.A or
7.B hereof, the Company shall have the right to cease making any payments, or providing other benefits, under this Agreement. The rights and remedies enumerated in this Section 8 shall be 

  

 5 

 
independent of each other, and shall be severally enforced, and such rights and remedies shall be in addition to, and not in lieu of, any other rights or
remedies available to the Company in law or in equity. 
 9.    Public Announcement 
 The Employee shall have the right to review any press release or other public announcement made by the Company in connection with the execution of this
Agreement and matters relating to this Agreement. The Company shall in good faith consider any suggestions that Employee communicates to the Company with reasonable promptness after receiving a draft of any such press release or other public
announcement, provided that the Company shall have the right in its sole discretion to make all final determinations with regard to any such press release or other public announcement. The Employee shall not make any public announcement concerning
his employment with or termination of employment from the Company nor make any private statement that is inconsistent with the Company’s public announcements, provided that the Employee shall not be precluded from providing truthful testimony
in a court of law, truthful statements to a government official, regulatory or law enforcement agency or pursuant to voluntary requests by SEC staff or a properly issued subpoena. 
 10.    Indemnification 
 The Company shall indemnify the Employee to the maximum
extent permitted by applicable law and the Company’s bylaws with respect to the Employee’s service to the Company, including the advancement of legal fees, and the Employee shall also be covered under a directors and officers liability
insurance policy(ies) paid for by the Company during the Employee’s employment with the Company. In no event whatsoever shall the Company pay, or agree to pay or indemnify, any disgorgement, interest or penalty amounts that the Employee is
ordered to pay by the SEC or a court of law in the SEC Action. The Company’s obligations under this Section 10 shall survive termination of the Employee’s service with the Company and also termination or expiration of this
Agreement. 
 11.    Release of Claims 
 The parties shall execute the General Release and Covenant Not to Sue attached hereto as Exhibit A (the “Release”). Notwithstanding anything contained herein to the contrary, the Severance Payment
shall be conditioned upon the Employee’s execution and non-revocation of the Release and compliance with the terms of the Release. 
 12.    Notices 
 All notices, requests and other communications pursuant to this Agreement shall be in
writing and shall be deemed to have been duly given, if delivered in person, by courier or by facsimile transmission, or sent by express, registered or certified mail, postage prepaid, addressed as follows: 
  

 6 

 If to the Employee: 
 Philip Bruce Camacho 
 2935 Gainesway Court 
 Cumming, GA 30041 
 with a copy to: 
 J. Peter Coll, Jr., Esq. 
 Orrick Herrington & Sutcliffe LLP 
 666 Fifth Avenue 
 New York, NY 10103-0001 
 If to the Company: 
 Bart Schwartz 
 Executive Vice President, Chief Legal Officer and Secretary 
 Assurant, Inc. 
 One Chase Manhattan Plaza 
 New York, NY 10005 
 with a copy to: 
 Paul J. Wessel, Esq. 
 Milbank, Tweed, Hadley & McCloy LLP 
 One Chase Manhattan Plaza 
 New York, NY 10005 
 Either party may, by
written notice to the other, change the address to which notices to such party are to be delivered or mailed. 
 13.    Tax Matters

 A.    Withholding of Taxes. 
 All Severance Payments and other benefits required to be provided by the Company to the Employee under this Agreement shall be subject to the withholding of such amounts relating to taxes and other payroll deductions
as the Company may reasonably determine it should withhold pursuant to any applicable law, regulation or Company policy. 
 B.    Section 409A of the Code. 
 The intent of the parties is that payments and benefits under this
Agreement comply with Section 409A and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance with Section 409A. In no event whatsoever shall the Company 

  

 7 

 
be liable for any additional tax, interest or penalties that may be imposed on the Employee by Section 409A or any damages for failing to comply with
Section 409A. 
 14.    Governing Law 
 This Agreement shall be construed, interpreted and enforced in accordance with the laws the State of New York, without giving effect to the choice of law principles thereof. 
 15.    Waiver of Breach 
 Any
waiver of any breach of this Agreement shall not be construed to be a continuing waiver or consent to any subsequent breach on the part either of the Employee or of the Company. 
 16.    Non-Assignment; Successors 
 Neither party hereto may assign his or its
rights or delegate his or its duties under this Agreement without the prior written consent of the other party; provided, however, that (i) this Agreement shall inure to the benefit of and be binding upon the successors and assigns of the
Company upon any sale of all or substantially all of the Company’s assets, or upon any merger, consolidation or reorganization of the Company with or into any other corporation, all as though such successors and assigns of the Company and their
respective successors and assigns were the Company, and (ii) this Agreement shall inure to the benefit of and be binding upon the heirs, assigns or designees of the Employee to the extent of any payments due to them hereunder. As used in this
Agreement, the term “Company” shall be deemed to refer to any such successor or assign of the Company referred to in this Section 16. 
 17.    Severability 
 If any provision of this Agreement is determined by a court of competent
jurisdiction to be not enforceable in the manner set forth in this Agreement, the Employee and the Company agree that it is the intention of the parties that such provision should be enforceable to the maximum extent possible under applicable law.
If any provision of this Agreement is held to be invalid or unenforceable, such invalidation or unenforceability shall not affect the validity or enforceability of any other provision of this Agreement (or any portion thereof). 
 18.    Entire Agreement 
 This
Agreement, together with the Consulting Agreement, constitutes the entire agreement by and between the Company and the Employee with respect to the subject matter hereof and supersedes any and all prior or contemporaneous agreements or
understandings between the Employee and the Company with respect to such subject matter, whether written or oral, including, without limitation the Employment Agreement. This Agreement may be amended or modified only by a written instrument executed
by the Employee and the Company. 
  

 8 

 19.    Acknowledgement; Attorneys’ Fees 
 The Employee acknowledges that the Company has advised him to seek and have the services and advice of legal counsel in reviewing and understanding this
Agreement and the Release prior to executing them, and that he has had the opportunity to obtain such services and advice in reviewing and understanding this Agreement and the Release prior to entering into them. The Employee further acknowledges
that the Release is intended to be legally binding and to cancel any and all rights of the Employee against the Company, and that he fully understands this Agreement and the Release contained herein and the legal effect thereof. The Company agrees
that it shall promptly pay Orrick, Herrington & Sutcliffe LLP for reasonable attorneys’ fees and expenses incurred in connection with entering into this Agreement, up to a maximum of $50,000, provided that the Employee submits to the
Company appropriate detailed invoices of such attorneys’ fees and expenses. 
 [SIGNATURES ON FOLLOWING PAGE] 
  

 9 

 IN WITNESS WHEREOF, the parties have executed this Agreement on the date first written above. 

 

	
	 EMPLOYEE

	
	 /s/ Philip Bruce Camacho

	 
	 Philip Bruce Camacho

  

			
	 ASSURANT, INC.

		
	 By:
	 	/s/ Bart Schwartz
	 Name:
	 	 Bart Schwartz

	 Title:
	 	 Executive Vice President and
 Chief Legal Officer

  

 10 

 EXHIBIT A 
 GENERAL RELEASE AND COVENANT NOT TO SUE 
 THIS GENERAL RELEASE AND COVENANT NOT TO SUE (this
“Release”) is entered into by and between Philip Bruce Camacho (the “Employee”) and Assurant, Inc. (the “Company”) pursuant to the terms of the Separation Agreement, dated as of March 3, 2009,
by and between the Employee and the Company, to which this Release is attached (the “Separation Agreement”). 
 1.    Release by the Employee 
 The Employee hereby releases and forever discharges, and covenants not to
sue, the Company or its subsidiaries, affiliates, their directors, members, officers, agents, stockholders, successors and assigns, both individually and in their official capacities, (the “Company Released Parties”) from, and with
respect to, any and all actions, causes of action, covenants, contracts, claims, demands, suits, and liabilities whatsoever, which the Employee ever had, now has or which his heirs, executors, administrators and assigns, or any of them hereafter
can, shall or may have by reason of or related to the Employee’s employment with, or termination of employment from, the Company and/or its subsidiaries and affiliates. 
 By signing this Release, the Employee is providing a complete waiver of all claims against the Company Released Parties that may have arisen, whether
known or unknown, up and until the effective date of this Release. This includes, but is not limited to, claims based on Title VII of the Civil Rights Act of 1964, the Civil Rights Act of 1866, the Age Discrimination in Employment Act of 1967
(including the Older Workers Benefit Protection Act) (the “ADEA”), the Americans With Disabilities Act, the Fair Labor Standards Act, the Equal Pay Act, the Family and Medical Leave Act, the Employee Retirement Income Security Act
of 1974 (except as to claims pertaining to vested benefits under employee benefit plans maintained by the Company Released Parties), and all applicable amendments to the foregoing acts and laws, or any common law, public policy, contract (whether
oral or written, express or implied) or tort law, and any other local, state or Federal law, regulation or ordinance having any bearing whatsoever on the terms and conditions of the Employee’s employment and the cessation thereof. 

The Employee further agrees, promises and covenants that, to the maximum extent permitted by law neither, he, nor any person, organization, or other
entity acting on his behalf has or will file, charge, claim, sue, or cause or permit to be filed, charged or claimed, any action for damages or other relief (including injunctive, declaratory, monetary or other relief) against the Company Released
Parties involving any matter occurring in the past up to the date of this Release, or involving or based upon any claims, demands, causes of action, obligations, damages or liabilities which are the subject of this Release. This Release shall not
affect the Employee’s rights under the Separation Agreement or under the Older Workers Benefit Protection Act to have a judicial determination of the validity of this Release and does not purport to limit any right the Employee may have to file
a charge under the ADEA or other civil rights statute or to participate in an investigation or proceeding conducted by the Equal Employment Opportunity 

 
Commission or other investigative agency. This Release does, however, waive and release any right to recover damages under the ADEA or any other civil rights
statute. 
 Notwithstanding anything to the contrary contained in this Release, nothing in this Section 1 shall apply to, or
release the Company from, any rights and claims of the Employee directly or indirectly arising from or under or related to any obligation or commitment of the Company under the Separation Agreement. 
 2.    Release by the Company 
 The
Company on behalf of itself and its subsidiaries and affiliates hereby releases and forever discharges, and covenants not to sue, the Employee from, and with respect to, any and all actions, causes of action, covenants, contracts, claims, demands,
suits, and liabilities whatsoever, which the Company ever had, now has or shall or may have by reason of or related to the Employee’s employment with, or termination of employment from, the Company and/or its subsidiaries and affiliates.

 The Company on behalf of itself and its subsidiaries and affiliates further agrees, promises and covenants that, to the maximum extent
permitted by law neither, they, nor any person, organization, or other entity acting on their behalf has or will file, charge, claim, sue, or cause or permit to be filed, charged or claimed, any action for damages or other relief (including
injunctive, declaratory, monetary or other relief) against the Employee involving any matter occurring in the past up to the date of this Release, or involving or based upon any claims, demands, causes of action, obligations, damages or liabilities
which are the subject of this Release. 
 Notwithstanding anything to the contrary contained in this Release, nothing in this
Section 2 shall apply to, or release the Employee from, any rights and claims of the Company or its subsidiaries and affiliates, or any liability he may have to the Company, directly or indirectly arising from or related to the
Separation Agreement. 
 3.    Review and Revocation Period; Acknowledgement 
 (a)    The Employee acknowledges that he has been given at least twenty-one (21) days to review this Release and has been given
the opportunity to consult with legal counsel, and he is signing this Release knowingly, voluntarily and with full understanding of its terms and effects, and he voluntarily accepts the severance payment and benefits provided for in the Separation
Agreement for the purpose of making full and final settlement of all claims referred to above. If the Employee has signed this Release prior to the expiration of the twenty-one (21) day period, he has done so voluntarily. The Employee also
understands that he has seven (7) days after executing this Release to revoke this Release, and that this Release will not become effective if he exercises his right to revoke his signature within seven (7) days of execution. 

(b)    The parties hereto acknowledge that they have not relied on any representations or statements not set forth in the
Separation Agreement or this Release. 
  

 2 

 4.    Legal Construction 
 This Release shall be governed by and construed in accordance with the laws of the State of New York. If any provision in this Release is held invalid or
unenforceable for any reason, the remaining provisions shall be construed as if the invalid or unenforceable provision(s) had not been included. 
 IN WITNESS WHEREOF, the parties have executed this Release on March 3, 2009. 
  

	
	EMPLOYEE
	
	 /s/ Philip Bruce Camacho

	 Philip Bruce Camacho

  

			
	 ASSURANT, INC.

		
	By:	 	/s/ Bart Schwartz
	 Name:  Bart Schwartz
 Title:    Executive Vice President and
              Chief Legal Officer

  

 3

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00155-of-00352.parquet"}]]